An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian...

Area of Science:

• Oncolytic virotherapy
• Cancer research
• Virology

Background:

• Oncolytic viruses, particularly those derived from herpes simplex virus (HSV), show promise for treating solid tumors like ovarian cancer.
• Existing oncolytic HSVs are exclusively based on herpes simplex virus type 1 (HSV-1).

Purpose of the Study:

• To develop and evaluate a novel oncolytic virus derived from herpes simplex virus type 2 (HSV-2).
• To assess the efficacy of this HSV-2-based virus against metastatic human ovarian cancer xenografts in vivo.
• To compare the therapeutic potential of the HSV-2-derived virus with an HSV-1-based oncolytic virus.

Main Methods:

• An oncolytic virus was engineered from HSV-2 by deleting the protein kinase domain of the ICP10 gene, targeting the Ras signaling pathway in tumor cells.
• The HSV-2-derived virus was administered intraperitoneally (i.p.) to nude mice bearing metastatic human ovarian tumor xenografts.
• Oncolytic activity was evaluated and compared to that of an HSV-1-based oncolytic virus using identical dosing and schedules.

Main Results:

• Intraperitoneal administration of the HSV-2-derived virus resulted in complete eradication of disseminated tumors in over 87% of mice after two doses.
• The HSV-1-based oncolytic virus achieved complete tumor eradication in only 12% of mice under the same treatment conditions (P<0.01).

Conclusions:

• The engineered HSV-2-based oncolytic virus exhibits potent antitumor activity against metastatic human ovarian cancer.
• Intraperitoneal administration of this HSV-2 oncolytic virus represents a promising therapeutic strategy for ovarian cancer.
• Further investigation into HSV-2-based oncolytic viruses may enhance cancer treatment options.